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Abstract
Background: Dose escalation of SBRT for locally advanced pancreatic cancer patients had been reported in several
studies in one or three fractions, and phase I protocol was developed to investigate the maximum tolerated dose
with CyberKnife for locally advanced unresectable pancreatic cancer patients in five fractions.
Methods: The study is designed as a mono-center phase I study. The primary endpoint is to determine the maximum
tolerated dose by frequency of III/IV GI (gastrointestinal) toxicity. Adverse events (AE) according to Common Toxicity
Criteria (CTC) version 4. Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5Gy x 5 respectively would be delivered while meeting
with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is
4 weeks from the first patient treatment to the next patient treatment at each dose level. The maximal tolerated dose
will be defined as the dose for which at least two patients in three, or at least three patients in nine, will present with a
limiting toxicity.
Discussion: Since the dose and fractions of SBRT treatment for locally advanced pancreatic cancer patients are still
unknown, we propose to conduct a Phase I study determining the maximum tolerated dose of CyberKnife SBRT for
the treatment of locally advanced pancreatic tumor based on a 5 fractions treatment regimen. This trial protocol has
been approved by the Ethics committee of Changhai hospital. The ethics number is 2016-030-01.
Trial registration: Clinical trials number: NCT02716207.
Date of registration: 20 March 2016.
Keywords: Locally advanced pancreatic cancer, SBRT study protocol
Background
Pancreatic cancer is the fourth-leading cause of cancer-
related death in the world. It is characterized by meta-
static spread and local failure and seldom detected in its
earlier stages. For locally advanced stage pancreatic can-
cer, the complete surgical removal is hard to achieve.
Stereotactic body radiotherapy (SBRT) with CyberKnife
for locally advanced unresectable pancreatic cancer is a
relatively new treatment option made available because of
significant improvements in diagnostic imaging and radi-
ation delivery techniques. Different from the conventional
radiotherapy, radiation dose is delivered in fewer fractions
and higher fractional doses in SBRT. Gurka [1] reported
that 14 patients received SBRT with prescription dose of
25 Gy in five fractions with BED (biologically equivalent
doses) of α/β = 10 in correspondence to 37.5Gy. Grade 1
to 2 gastrointestinal toxicity (no grade 3 or 4 radiation-
related toxicities) was observed 2 weeks after treatment.
Two patients had a partial response, and 12 patients were
with stable diseases. In the previous dose escalation study,
a single fraction upto15 Gy, 20 Gy, 25 Gywhich is an
equivalent BED10 to 37.5Gy,60Gy,87.5Gy respectively is
recommended by Koong AC [2] and his team. Even
though the local control rate is 100%, the follow up is
short and the sample size of 15 patients is relatively small.
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Moreover, the late toxicity is not investigated. And with
single fraction scheme, higher late GI toxicities were re-
ported [2–4]. In the meanwhile, investigators [5, 6] from
South Korea examined that a Dmax of 35Gy and 38Gy in
3 fractions (BED10 to75.8Gy and 86.1Gy) of SBRT corre-
lated with a 5 and 10% rate of grade 3 of gastroduodenal
toxicity for abdominal malignant tumor, respectively.
Chuong [7] used 5 fractions to potentially decrease the
risk of late normal tissue injury compared with 1 to 3
fractions commonly used in other institutions. Assuming
α/β = 3, the EQD2 = nd*(d + α/β/2 + α/β) delivered to
normal tissue in this study (using a mean 36.4 Gy in 5
fractions to the high dose PTV) was 75Gy, which is
lower than the mean EQD2 from other series, the corre-
sponding values from Boston and Stanford were 92.2Gy
(mean, 32.96 Gy in 3 fractions) and 140Gy (mean, 25Gy
in 1 fraction), respectively [8, 9]. And a relatively lower




The study is designed as a mono-center phase I study to
evaluate the maximum tolerated dose for locally advanced
unresectable pancreatic cancer treated with CyberKnife
SBRT.
Primary endpoint
To determine the maximum tolerated dose.
Secondary endpoints
1. To assess the pain intensity by NRS scores.
2. To assess acute and late toxicities following
CyberKnife SBRT.
3. Response rate by RECIST criteria.
4. Relapse-free survival (RFS) and overall survival (OS).
Inclusion criteria
Locally advanced unresectable pancreatic adenocarcin-
oma which is proved by biopsy.
A life expectancy of >3 months
KPS ≥70
Tumor size <5 cm
Tumor location: head of pancreas
Age of 18–75 years old
Patients must be able to undergo contrast enhanced
CT for planning
Absolute neutrophil count ≥ 1,5 × 109cells/L
Leukocyte count ≥ 3.5 × 109cells/L
Platelets ≥ 70 × 109cells/L
Hemoglobin ≥ 8.0 g/dl
Albumin >2.5 g/dL
Total bilirubin < 3 mg/dL
Creatinine < 2.0 mg/dL
INR < 2 (0.9–1.1)
AST < 2.5 × ULN (Upper Limit of Normal) (0–64U/L)
ALT < 2.5 × ULN (0–64U/L).
Both men and women and members of all races and
ethnic groups are eligible for this study.
Ability of the research subject or authorized legal rep-
resentative to understand and the willingness to sign a
written informed consent document.
Tumor markers and lab test should be done less than
1 week before recruitment.
Exclusion criteria
Prior surgery, chemotherapy or radiation for pancreatic
tumor.
Prior radiotherapy of the upper abdomen, evidence of
metastatic disease such as nodal or distant metastases by
abdomen CT and chest CT.
Contraindication to receiving radiotherapy.
Distance between GTV (lesion) and luminal structures
(including liver, stomach, duodenum, small or large bowel)
is less than 5 mm.
Women who are pregnant or participation in another
clinical treatment trial while on study.
Patients in whom fiducial implantation were not possible.
Radiation treatment planning
SBRT will be delivered on CyberKnife with Synchrony
Respiratory Tracking system. The tumor will be tracked
with implanted fiducial markers by Fiducial Tracking
System. Treatment will be delivered in 5 fractions within
1 to 2 weeks at the discretion of the investigator.
A body fixation (vacuum-bag) will be used in immobil-
izing the body, the arms (both arms are along the body)
and the legs.
Dose will be administered according to the following
recommended schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy,
8.5 Gy, 9 Gy, 9.5Gy x 5 with BED10 in correspondence
to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy re-
spectively would be delivered while meeting with normal
tissue constraints (Table 1). A minimum of three pa-
tients will be included for each dosage level. And an
interval is 4 weeks from the first patient treatment to
the next patient treatment at each dose level. In case
Table 1 Diagram of dose escalation
Level Dose (Gy) Fractions Total (Gy)
1 7 5 35
2 7.5 5 37.5
3 8 5 40
4 8.5 5 42.5
5 9 5 45
6 9.5 5 47.5
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patient presents III/IV GI toxicity, three additional pa-
tients will be included at the same dose level.
The maximal tolerated dose will be defined as the dose
for which at least patients in 3, or at least three patients
in 9, will present with a limiting toxicity.
Margins: The Gross Tumor Volume (GTV) is defined
as the visible tumor based on contrast enhanced CT ac-
quired on portal-venous phase. The clinical target vol-
ume (CTV) equals the GTV. The planning target
volume (PTV) was usually defined as the region of 2–
5 mm outside of CTV. When tumor is adjacent to crit-
ical organs especially duodenum, we choose to avoid
expanding PTV outside of CTV in this direction.
An individualized treatment plan will be developed
based on tumor geometry and location. At least 90% vol-
ume of PTV should be covered by the prescription dose.
The prescription isodose line was limited to 70–75%
which will restrict tumor Dmax. e. If dose level violates
the constraint of SBRT, the patient will be considered as
ineligible for this trial (Table 2).
Fiducial (Soft tissue gold markers, 0.9 × 3 mm, CIVCO,
Orange City, lowa 51041 USA) implantation will be
done under endoscopic ultrasonography (EUS) guidance.
The recommended number of implanted fiducials is 3
(at least 1) which is preferable to be close to, but not in
the tumor. A time-period of 4–7 days between implant-
ation and treatment planning CT-scan is recommended.
Intervention and mode of delivery
The planning CT scan and enhanced pancreatic paren-
chymal phase CT should be acquired under breath hold
(preferably end-expiratory). The scan range includes the
whole pancreas, at least 10 cm above and below the
tumor. The spiral thin-slice CT was with 1.5 mm slice
collimation and images were reconstructed in slices of
1.5 mm at the most. Co-registration of planning CT to
contrast enhanced CT is based on fiducial and
anatomical (spinal) fusion. With fiducials >3, 3D data
could be tracked whereas it is hard to implant three fi-
ducials in clinical practice. If fiducials <3, method of 1 fi-
ducial plus X-sight spine and Synchrony Tracking
technique will be applied. Before the treatment, DRR im-
ages on spine will be applied to detect the 6-D error and
correction will be done thereafter for the X-sight spine
tracking on patients’ positioning. During treatment, fidu-
cial tracking will be applied.
The irradiation planning and radiation techniques
Collimator selection: there are 12 size options for colli-
mators selections from 5 to 60 mm, and it depends on
tumor size and the distance to organ at risk (OAR). To
improve the treatment efficiency, the collimator size for
each enrolled patient is fixed in our study.
MU limit is set up to avoid large MU for single beam.
And the total MU is 90,000 for 5 fractions. Maximum
MU/beam is limited to 500 and maximum MU/node is
limited to 1600.
PTV is taken as the source, and shells are expanded
isotropically to constrain high dose volume outside tar-
get and increase conformity index of PTV.
OCO (optimize coverage) technique is applied to
optimize coverage and conformity.
Beam reduction technique is applied to increase treat-
ment efficiency by deleting beams with small MU.
High resolution is applied to the treatment planning to
further optimize and normalize the prescription dose.
Duration of intervention and evaluation
The duration of treatment will be 1 to 2 weeks. It is de-
livered every day and 5 times a week. In case of machine
breakdown, it will be extended to 2 weeks. The follow-
up period will be for 1 year following completion of
therapy. The trial is planned to begin on September
2016. There cruitment period of the entire study (27 pa-
tients) will take approximately 1 year. Acute and late
toxicity according to CTCAE 4.0will be evaluated. Triple
phase enhanced abdomen CT scan (<4 weeks), physical
examination and lab test will be assessed at 1, 3, 6, 9,
12 months after completion of treatment.
A quality assurance
SBRT QA group will be established by two radiation on-
cologists and two physicists.
Discussion
Since the treatment modality and dose are still under ex-
ploratory stage, we propose to conduct a Phase I study
determining the maximum tolerated dose of CyberKnife
SBRT for the treatment of locally advanced pancreatic
tumor based on a 5 fractions treatment regimen. A pre-
scription dose of 35–47.5 Gy in five fractions was
Table 2 Critical structures and constraints
Organ Dose limits (5 fractions) Volume
Liver 17.5 Gy ≥700 cc spared
Kidney <12 Gy Dmean
Spinal cord 23 Gy 0.35 cc
Spinal cord 27Gy Dmax
Duodenum 18Gy 5 cc
Duodenum 12Gy 10 cc
Small bowel 19.5Gy 5 cc
Stomach 18Gy 10 cc
Esophagus 19.5Gy 5 cc
Large Bowel 25Gy 20 cc
Based on The Report of AAPM (American Association of Physicists in Medicine)
Task Group 101
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chosen, with an equivalent to the traditional dose of
2 Gy in 25–39 fractions of BED10. And this is assumed
to be the safe and effective dose for unresectable pancre-
atic cancer patients.
Initial dose: No severe gastrointestinal toxicities were
reported when Dmax to the gastrointestinal organs was
within 30 Gy [10, 11]. Based on these results, Kavanagh
[12] suggested that Dmax of the intestine should be less
than 30 Gy in three fractions (BED10 to 60 Gy). The ini-
tial dose in our study will be defined as 35 Gy in 5 frac-
tions (BED10 to 59.5 Gy), which is an equivalent to the
traditional dose of 2 Gy in 25 fractions in BED10.
The classical “4R” radiobiological factors and linear-
quadratic (LQ) model are useful for calculating iso-effect
doses in conventional 2Gy fractionated irradiation, which
is not enough for estimating hypo-fractionated SBRT [13].
The SBRT may prolong the time of repairing sub-lethal
radiation damage compared to conventional irradiation in
mamalian cells [14]. Moreover many evidences show that
DNA double-strand breaks alone cannot explain the
highly effective SBRT [15, 16], which encompasses not
only direct but also indirect cell deaths [17] including dif-
ferential endothelial, overcoming hypoxic radio resistance
and activation of immunological pathways.
These biological properties may contribute to reduce
normal tissue toxicity and hypofractionation is more ef-
fective than conventional radiation therapy.
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